US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
AAPL
$333.69
▲+1.02%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
541.70
-29.68 (-5.19%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
October 01, 2026
Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ...
Via
StockStory
Topics
Intellectual Property
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
October 01, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via
StockStory
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
September 30, 2026
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled t...
Via
StockStory
Topics
Intellectual Property
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions
↗
September 25, 2026
United Therapeutics (NASDAQ:UTHR) outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors...
Via
MarketBeat
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate
↗
September 24, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock
↗
September 21, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model
↗
September 03, 2026
Via
Chartmill
Why United Therapeutics (UTHR) Shares Are Falling Today
September 24, 2026
What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of t...
Via
StockStory
1 Cash-Heavy Stock to Target This Week and 2 We Question
September 11, 2026
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Via
StockStory
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
September 08, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove...
Via
StockStory
Topics
Artificial Intelligence
3 Profitable Stocks We’re Skeptical Of
September 03, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns
↗
August 20, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play
↗
August 13, 2026
Via
Chartmill
United Therapeutics (NASDAQ:UTHR) Tumbles as Q2 Revenue Misses Despite EPS Beat
↗
August 05, 2026
Via
Chartmill
3 Cash-Producing Stocks We Keep Off Our Radar
August 26, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
CEO Rothblatt calls H1 2026 "one of the most consequential periods" in company history.
Via
The Motley Fool
Topics
Earnings
United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
August 12, 2026
United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting ...
Via
StockStory
Topics
Earnings
UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
August 06, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) beat Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 m...
Via
StockStory
United Therapeutics Q2 Earnings Call Highlights
↗
August 05, 2026
United Therapeutics (NASDAQ:UTHR) reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized...
Via
MarketBeat
Topics
Earnings
United Therapeutics (NASDAQ:UTHR) Surprises With Q2 CY2026 Sales
August 05, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 1.9% year on yea...
Via
StockStory
Topics
Artificial Intelligence
Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow
August 03, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting results this Wednesday before the bell. Here’s what you need to know. United Therap...
Via
StockStory
United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?
↗
July 28, 2026
Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while maintaining $353.1 million in equity value.
Via
The Motley Fool
Topics
Regulatory Compliance
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
June 22, 2026
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q1 therapeutics earnings season. Over the next ...
Via
StockStory
Topics
Artificial Intelligence
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
June 21, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
Via
StockStory
Topics
Artificial Intelligence
These 3 Stocks Lowered Their Share Counts Drastically in Q1
↗
June 09, 2026
Pinterest, Southwest Airlines, and United Therapeutics each executed significant share repurchases in Q1 2026, reducing their outstanding share counts by 16%, 5%, and 3.2%, respectively.
Via
MarketBeat
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
June 03, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via
StockStory
Topics
Energy
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
↗
May 30, 2026
Ultragenyx develops therapies for rare genetic diseases, with a portfolio spanning approved biologics and a pipeline of gene therapies.
Via
The Motley Fool
Topics
Regulatory Compliance
2 Mid-Cap Stocks on Our Buy List and 1 We Turn Down
May 29, 2026
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Via
StockStory
Topics
Credit Cards
5 Insightful Analyst Questions From United Therapeutics’s Q1 Earnings Call
May 13, 2026
United Therapeutics' first quarter results fell below Wall Street's revenue and earnings expectations, but the market responded favorably. Management attribu...
Via
StockStory
Topics
Earnings
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
May 07, 2026
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
